BridgeBio Pharma (BBIO) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- -$0.78
- Estimate
- -$0.58
- Surprise
- -33.9%
- Revenue (period 2026-06-30)
- $243.7M
- Score at report (before → after)
- 5.3 → 5.4/10
Revenue source: xbrl.
How the report landed
BridgeBio Pharma (BBIO) reported a wider loss than forecast — adjusted EPS of -$0.78 against the -$0.58 estimate (a 33.9% shortfall). TrendMatrix's engine moved from Buy (Wait) (5.3/10) to Sell at 5.4/10 after the report — the engine's score rose despite the miss.
Where TrendMatrix's rating stands now
TrendMatrix currently rates BBIO Sell at 5.6/10.
1 of the last 4 quarters beat the estimate; this quarter's -33.9% surprise compares with a -28.2% four-quarter average. Next scheduled report: 2026-10-28.
What argues against it
- Concentration risk — Product: Attruby and Beyonttra
- Quality below floor (4.0 < 4.0)
- Momentum score 2.6/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $65.71
- Price target
- $98.19
- Stop
- $62.95
- Upside to target
- +49.4%
- Reward-to-risk
- 5.8:1
Risk check: RSI 21 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-09-24 — shown for context, not personalized investment advice.
BBIO at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $12.85B
- P/E (fwd)
- 2392.1
- 52-week range
- $48.78–$93.42
- Off 52-week high
- 29.7%
- RSI (14)
- 21
- Volume vs avg
- 1.49×
- Score today
- 5.6/10